NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Laigo Bio

Laigo Bio

Private
UtrechtHealthcare & Life Scienceshttps://www.laigobio.com/en/

Last Round

Seed

Mar 23, 2026

Total Funding Raised

$31.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Laigo Bio is a biotechnology company that develops bispecific antibody-based therapeutics for oncology and immunology using its proprietary SureTAC™ precision membrane protein degradation platform.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

SureTACtargeted protein degradationTPDprotein degradermembrane protein targetingbispecific antibodiesundruggable targetsdrug discovery platformE3 ligaseoncology therapeuticsSurface Removal Targeting Chimerasimmunology therapeuticsautoimmune disease therapyneuroinflammation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Laigo Bio Comparables

Compare Laigo Bio with similar companies based on industry and business-model similarity.

Laigo Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GlycoEra
82%
Avilar Therapeutics
81%
Johnson & Johnson
80%

Laigo Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 23, 2026
SeedDec 4, 2025
SeedFeb 8, 2022

Laigo Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 126% MoM.

  • Apr 26, 2026

    Grew 64% QoQ from 11 to 18 employees.

Laigo Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Laigo Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Laigo Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersUtrecht
Employee Range20
Year Founded2022
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.